T he hallmark of sepsis syndrome is an intense inflammatory response. The pathogenesis of the conditions is now becoming better understood. Increasing evidence implicates the production of proinflammatory cytokines, adhesion molecules, vasoactive mediators, and reactive oxygen species in the immunoinflammatory process common to both systemic inflammatory response syndrome and sepsis (1) .
Statins inhibit 3-hydroxy-3 methylglutaryl coenzyme A reductase and recently have been postulated to have beneficial effects on anti-inflammatory and immunomodulatory. Furthermore, statins may have a direct antimicrobial effect (1) . Early data suggest statins to be beneficial before and after septic insults. When mice were challenged with endotoxin lipopolysaccharide, pretreatment of statins restored responsiveness to the vasopressor phenylephrine by reducing nitric oxide production (2) . In healthy volunteers treated with Escherichia coli endotoxin, simvastatin was able to restore radial artery responsiveness to norepinephrine and acetylcholine (3) . In the study by Buerke et al (4) , pretreatment with simvastatin protected against Staphylococcus aureus -toxin-induced sepsis associated with reduced p53, tumor necrosis factor-, apoptosis, and necrosis with improvement in systemic hemodynamics, coronary perfusion pressure and myocardial function in a mouse model. In the study by Merx et al (5) , mice treated with statins hours after a septic insult demonstrated significantly increased survival times as a result of the restoration of cardiac function and hemodynamic status.
Statins may be a good candidate as novel therapeutic agents for the treatment and prevention of sepsis. To date, there have been no large randomized controlled trial investigating the role of statins in sepsis. Three observational studies published for patients particularly with bacteremia over the past 10 yrs in which two of them showed potential benefits (6) (7) (8) . However, each study had its imperative limitations. In general, they all demonstrated that the baseline characteristics and comorbidities were clearly different between groups, thus susceptible to confounding by indications for statin therapy. In addition, the definition of statin use was dissimilar in all three studies. In the study by Thomsen et al (6) , the data of statin use were retrieved from an outpatient prescription database with a lack of data on inpatient use when the Objective: The pleiotropic effects of statins, 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor, have been shown to modify inflammatory cell signaling on the immune response to infection. It was postulated that statins may be a good candidate as novel therapeutic agents for the treatment of sepsis. We investigated whether ongoing statin therapy is associated with mortality in patients with bloodstream infection.
Design: A retrospective cohort study. KEy WORdS: bacteremia; cohort study; mortality; propensity score analysis; sepsis; statins patients were hospitalized with bacteremia. The study by Liappis et al (7) only included patients taking statins throughout the course of hospitalization, which may indicate these patients were clinically more stable to allow continuation of statin therapy that may result in selection bias. Despite a potential benefit, the types of statins were not examined.
The objective of this study was to further define the association between statin therapy and mortality among hospitalized patients with bacteremia after accounting for baseline differences between statin users and nonusers. We hypothesize that patients on statin therapy before a bacteremic episode would have improved hospital survival compared with bacteremic hospitalized patients not on statins.
METHODS
Study Subjects and Design. We performed a retrospective cohort study of patients with culture-positive bacteremia at Weiler Hospital and the Moses Division of the Montefiore Medical Center (both in Bronx, NY) from January 1, 2008, to December 31, 2009. Patients were eligible for inclusion if they were 18 yrs and had at least one documented positive blood culture during hospitalization. Bacteremia was defined as one or more blood cultures positive for potential pathogenic organism isolated from a patient during hospitalization. For common skin contaminant (see Supplemental Table 1 [Supplemental Digital Content 1, http://links. lww.com/CCM/A367 ]), two or more positive blood cultures drawn on separate occasions were required for bacteremia (9) . Patients were excluded in whom all organisms identified from the blood culture are considered to be common skin contaminants. For patients with multiple episodes of bacteremia within the same admission, only the first episode of bacteremia was analyzed. This study was approved by the Montefiore Medical Center institutional review board and the need for patient consent was waived.
Data Collection and Measurement. The exposure of interest was ongoing statin therapy at the time of positive culture for bacteremia. Statin therapy was defined as administration of any statin medication at the time blood culture was sampling and/ or documentation of statin use as an outpatient before hospitalization if the bacteremic blood culture was drawn within 24 hrs of admission. We identified 592 patients who had received statin therapy, in which 551 (93.1%) received treatment as an outpatient and 173 (29.2%) received treatment as an inpatient before sampling of blood culture. One hundred eighty patients discontinued statin therapy after sampling of blood culture and 412 patients continued their statin therapy during their hospitalization. For those who received statin therapy during hospitalization, the minimal number of days of statin administration was 1 day at the time of blood culture sampling. Chart review was used to extract information on outpatient medication and the site of infection. The electronic patient record was reviewed to isolate data on physiological parameters, laboratory parameters, inpatient medication records, use of mechanical ventilation and noninvasive positive pressure ventilation, intensive care unit (ICU) admission and transfer, ICU and hospital length of stay (LOS), and inhouse mortality. The definition of sepsis was fulfilling two or more following criteria and a proven infection: temperature >100.4F or <96.5F; heart rate >90 beats/min; respiratory rate >20 breaths/min; and white blood cell >12,000 cells/mm 3 or <4000 cells/mm 3 (10) . A random sample of 5% of the charts was reassessed to verify data entry and to ensure accuracy. Study Outcomes. The primary study outcome was 90-day all-cause mortality from date of sampling of blood culture, which was based on a publicly available database, the Social Security Death Master File. The Social Security Administration receives approximately 90% of its death notifications from funeral homes, friends, and relatives of the deceased; 5% from postal authorities and financial institutions; and 5% are derived from computer matches with federal and state agency data. The file is updated on a weekly basis. The date of death of the deceased was obtained by matching the Social Security number from the database. In our cohort of 2,177 patients with eligible bacteremia, 2,129 (97.8%) had a Social Security number. Of the remaining 48 patients, ten died during hospitalization. Because we could not determine the survival data on the other 38 (1.7%) patients who had missing Social Security numbers, they were excluded from the final cohort. Secondary outcome included ICU admission, ICU and hospital LOS, and acute respiratory failure indicated by the need of mechanical ventilation and noninvasive positive pressure ventilation.
Statistical Analysis. Baseline characteristics of the study groups were compared with the Fisher's exact test for categorical variables and t test for continuous variables. Nonnormally distributed continuous variables were analyzed with Wilcoxon's rank sum test.
Stepwise backward Cox proportional hazards regression was used to determine factors associated with 90-day all-cause mortality. The initial model consisted of all the independent variables that have a p < .25 in the bivariate analysis. Variables were removed one at a time if they did not contribute to the model assessed by the likelihood ratio test (p < .05) and they did not contribute to the model as a confounder defined by change in estimate of 15% of the  coefficient for the variable. We then expanded the model to include inter action terms with statins and biological plausible independent variables (age, gender, race, body mass index, and Charlson score). No interaction was found (p > .192). To evaluate whether there is any violation of the Cox proportional hazard assumptions, a graphical approach using log-log plots and a statistical approach using goodness-of-fit with Schoenfeld residuals were used and no violations were found.
The major limitation of observational studies is unequal distributions of important covariates between comparison groups because random assignment is impossible. To minimize biases, propensity score analysis was used. Variables were chosen for inclusion into the propensity score calculation according to the methods of Brookhart et al and included variables associated with statin use (age, gender, race, body mass index, use of -blocker, angiotensin-converting enzyme, angiotensin II receptor blockers and aspirin, history of myocardial infarction, cerebrovascular accident, congestive heart failure, peripheral vascular disease, diabetes mellitus with and without complications, pulmonary disease, mild liver disease, renal disease, malignancy, HIV/AIDS, and dementia) and variables associated with the outcome (nursing home residents, hospital acquired infection, recent admission within 2 months, pneumonia, unknown source of infection, sepsis, Acute Physiology Age Chronic Health Evaluation II, low systolic blood pressure, low diastolic blood pressure, bradycardia, tachycardia, tachypnea, hypothermia, hyperthermia, hypoalbuminemia, high international normalized ratio and low platelets, elevated aspartate transami nase and alanine transaminase, and low bicarbonate [11] ).
For the propensity score analysis, two approaches were used. First, users and nonusers were matched by propensity score using conventional greedy algorithms with nearest neighbor matching minimizing the absolute difference between propensity score with no match exceeding the predetermined caliper of 0.25 of SD of the sample estimated propensity scores. A 0.015 caliper of propensity was used. Second, multivariate analysis was used after stratification by deciles of propensity score. The Breslow-Day test for homogeneity of the hazard ratios was performed, and the Mantel-Haenszel estimate of the pooled hazard ratio was determined. This approach allowed full use of the data and also stratum-by-stratum estimates of the statins hazard ratio.
To address the association of statins in bacteremic patients who fulfill criteria for sepsis, we performed a sensitivity analysis with an adjusted Cox regression restrictive to those patients (1735 of 2139) who met the criteria of sepsis within 24 hrs before or after the bacteremic episode. The logistics were the same as those for performing multivariate Cox regression described previously. Furthermore, to account for the lack of independence between cohorts induced by matching, a sensitivity analysis using unadjusted Cox regression stratified on the matched pairs was performed.
For secondary outcomes of ICU and hospital LOS, a multivariate linear regression model was used. Stepwise backward multivariate linear regression was used to determine factors associated with LOS. The model consisted of all the independent variables that have a p < .25 in the bivariate analysis. Variables were removed one at a time after determining that there was no significant change in the regression coefficient of statins (<15%). Potential effect modifiers were explored, and interaction between all the variables and statins with biological plausibility was tested and no interaction was found (p > .428). Histogram, pp-plot confirms normality of raw, standardized, and Studentized residuals. Residual-vs.-fitted and residualvs.-predictors and component-plus-residual plot and locally weighted scatterplot smoothing graphically confirmed that the assumptions of linearity and equal variance were not moderately violated.
For secondary outcomes of acute respiratory failure, a surrogate marker as the need of mechanical ventilation and/or noninvasive positive pressure ventilation was analyzed using stepwise backward multivariate logistic regression methods. The logistics were the same as those for performing multivariate linear regression described above.
All statistical analyses were performed using Stata version 11.2 (StataCorp, College Station, TX) software with two-sided tests. p < .05 was considered statistically significant.
RESULTS
Baseline Characteristics. During the 2-yr period, 2139 patients were hospitalized with the first episode of bloodstream infection of whom 49% were men with a mean age of 64 6 17 yrs. Statin therapy was administered to 592 (27.7%) patients with bacteremia ( Fig. 1) . Overall, there were a total of 451 patients on simvastatin, 98 on atorvastatin, eight on pravastatin, 24 on lovastatin, and 11 on rosuvastatin who were taking statins as an outpatient and/or inpatient before bacteremia.
The baseline demographics, preexisting medical conditions, and relevant clinical, physiological, and laboratory parameters of the study groups are summarized in Table 1 . Statin users were older with higher body mass index, and they were less likely to receiving antibiotics within 6 hrs, had higher rates of myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident, pulmonary disease, diabetes, and renal disease, whereas nonstatin users acquired more infections during hospitalization and had more malignancy and HIV/AIDS and less mild liver disease ( Table 1) . Use of -blockers, angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, and aspirin was higher in the statin group. Statin users had higher Acute Physiology Age Chronic Health Evaluation II score but less sepsis syndrome than nonstatin users. Vascular access catheter infections and urinary tract infection were higher in the statin group, whereas respiratory and unknown source of infection as well as Streptococcus pneumoniae infections were higher in the nonstatin group. Serum creatinine and white cell counts were higher in the statin group on the day of being culture-positive, whereas serum albumin, bicarbonate, and platelet count were lower in the nonstatin group.
In creating a propensity score for each subject, 32 were excluded because no propensity score was assigned as a result of missing data. Propensity score matches were found for 447 (75.5%) of 592 patients receiving statin therapy. The matching process eliminated all significant differences that existed between both groups regarding patient demographics, epidemiologic factors, preexisting medical conditions, physiological and laboratory parameters, source of infection, and acquired pathogens ( Table 1 ). The only significant difference between groups found was the higher percentage of patients who received antibiotics within 6 hrs at the time of bacteremia in the nonstatin group (Table 1) .
Mortality. The main clinical outcomes are shown in Table 2 . All cause inhouse and 90-day mortality, ICU admission, and use of mechanical ventilation were statistically significantly higher in the nonstatin group in the bivariate analysis. In the unmatched cohort, the adjusted Cox proportional hazards model showed a 22% decreased hazard in death in the statin users compared with the nonstatin users and it was statistically significant (hazard ratio [HR] 0.78; 95% confidence interval [CI] 0.65-0.94).
We performed a propensity scorematched analysis between statin users and nonusers based on caliper matching as outlined previously. The mean 6 SD of the propensity score of the statin and nonstatin groups were 0.39 6 0.20 and 0.38 6 0.20, respectively. In the adjusted Cox analysis, there was no statistically significant association between statin therapy and 90-day all-cause mortality (HR 0.99; 95% CI 0.77-1.25). The details of the multivariate Cox analysis are shown in Table 3 . In a subgroup analysis for different types of statins compared with nonusers, there was no association with Table 4 .
Sensitivity Analyses. Because the hypothesis of statin use is to target the systemic inflammatory response to (14); bfrom hospital admission to sampling of blood culture. infection, to investigate this further, an additional Cox regression model was performed on patients who met the sepsis criteria. There were 350 in the statin treatment group and 358 in the nontreatment group. The mean 6 SD of the propensity score of the statin and nonstatin groups were 0.38 6 0.20 and 0.37 6 0.21, respectively (p = .683).
In the adjusted Cox analysis, there was no statistically significant association between statin therapy and 90-day all-cause mortality (HR 0.86; 95% CI 0.66-1.12).
A second approach to the sensitivity analyses was conducted that an unadjusted Cox regression stratified on the matched pairs to account for the lack of independence between cohorts induced by matching. The pooled HR from the Mantel-Haenszel test was found to be 1.00 (95% CI 0.77-1.30).
Secondary Outcomes. The main secondary clinical outcomes are shown in Table 2 . The need for mechanical ventilation/noninvasive positive pressure ventilation, ICU admission, ICU LOS, and hospital LOS were not significantly different in the two groups.
DISCUSSION
In this present work, we aimed to better define the association between statin therapy and survival after bacteremia. Although the crude analysis indicated a protective effect with statin therapy in patients with bacteremia, there were numerous significant differences in the baseline characteristics and clinical parameters between the groups, indicating that the propensity of receiving statins was intrinsically different. To address confounding by the indication for statin use, a propensity score analysis was used. In the propensity score-matched analysis, the association disappeared. The adjusted analysis by deciles of propensity score further confirmed this finding. For the secondary outcomes, statin therapy was not associated with the reduction of ICU admission, ICU and hospital LOS, or acute respiratory failure.
Over the last decade, statins have been studied extensively in the animal model and the preclinical evidence has been promising. However, in the clinical setting, observational studies in humans have shown mixed results (6) (7) (8) . A recent meta-analysis from Tleyjeh and colleagues (12) was carefully carried out. The role of statins was analyzed separately between the treatment and prevention cohorts. In the nine treatment cohorts (three on bacteremia, three on pneumonia, two on sepsis, and one on bacterial infection), the pooled adjusted effect estimate was 0.55 (95% CI 0.35-0.83) in favor of statins. The author pointed out that there was evidence of heterogeneity and publication bias. Among the three studies that examined patients with bacteremia, the sample sizes of the statin groups were small (ranging from 35 to 176 patients) (6) (7) (8) . The baseline characteristics and comorbidities were evidently different between the groups. The cohort from Liappis et al was in a veterans' hospital with predominantly male (99.5%) patients. The study was also restricted only to Gram-negative bacilli and S. aureus pathogens. They found that statins decreased 87% risk of all-cause inhospital mortality with a widened 95% CI between 0.11 and 0.99 (7) . However, no other prognostic predictor, including age or comorbidity, was reportedly associated with mortality in their model. In the study by Thomsen et al (6) , the prevalence of statin use was extremely low (3.3%). They used the prescription of statins from a pharmacy database as a surrogate for statin therapy. This longterm adherence of statin users may be a marker for unmeasured factors associated with a better prognosis and attributed to healthy user effect. Nevertheless, the study did not show a mortality benefit at the 30-day mark (HR 0.93; 95% CI 0.66-1.30). Lastly, a study by Kruger et al (8) studied 438 patients with bacteremia. Sixty-six patients were prescribed with statin before admission, and 56 of them continued statin therapy during their bacteremia episode. Mortality was lower in the statin group (odds ratio, 0.06; 95% CI 0.0008-0.43), but it raised a concern as to whether these patients are clinically more stable to allow continuation of statin therapy.
The definitive way to answer our research question would be to conduct a large clinical trial in which patients are randomized to receive statin therapy with suspected bacteremia on admission and to determine whether statin therapy would improve survival after an eligible bloodstream infection. One randomized prospective trial involved 150 subjects investigated the benefit of continuation of statin in sepsis in patients already on a statin (13) . No survival benefit to continuing statin therapy was found after accounting for differences between groups. Currently, there are a few randomized controlled trials ongoing, including the HARP 2 trial (Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction ISRCTN88244364) and the SAILS trials (Statins for Acutely Injured Lungs from Sepsis, clinicaltrials.gov identifier NCT00979121). They both aim to examine the effect of statins in acute lung injury.
Statins seem to influence a broad array of pathogenic micro-organisms and appear to decrease the infectivity and replication rates of a number of micro-organisms. However, whether statins have the same effect on endotoxin and exotoxin has not been examined. In our study, we failed to show that statins has a different effect between these toxins.
Our study has a number of notable strengths. Unlike other several prior investigations, baseline differences between patients prescribed statins and those who were not were more rigorously accounted for and balanced between statin users and nonusers with propensity score analysis. In addition, other cardiovascular medications such as -blockers, aspirin, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers were adjusted in the model, because very often, patients who are on statin therapy are also treated with these medications. Also, the sample size of the statin group as well as the matched cohort was the largest compared with another bacteremia cohort. Lastly, distinct from all other observational studies, we included the types of statins used in our study.
We acknowledge the retrospective observational design of the present study. Even as propensity score matching was used, these results do not account for important unmeasured confounding, e.g., inappropriate empirical antimicrobial treatment and patients who were in septic shock. However, we included the Acute Physiology Age Chronic Health Evaluation II score at the time of blood culture sampling, which serves as a surrogate of severity of illness. Second, although we only examined patients with bloodstream infections, we did not include all patients with sepsis. Third, we did not have data on indications or duration of statin therapy before admission.
CONCLUSION
In this retrospective, large cohort propensity-matched study, we were not able to find evidence of survival benefits with statin therapy. Statin therapy was not associated with reducing acute respiratory failure, ICU admission, and ICU and hospital LOS. Given that the discrepant findings from observational studies and preclinical evidence, a large randomized controlled trial administering statins as a therapeutic agent in patients with bacteremia is warranted.
